INVESTBOARDLog in
Healthcare · Drug Manufacturers - General · US

Pfizer Inc PFE

$29.23 · close of Nov 9, 2026

Compounding R&D engine protected by regulatory exclusivity and manufacturing scale sustains high-margin cash flows across therapeutic cycles.

AI score · Solid · analysis Aug 11, 2026
6.2 of 10

Valuation holds this up; Risk is the soft spot.

Moat5.0
Management7.0
Valuation8.0
Risk · 10 = lowest5.0
Business model6.0
Optionality6.0
Fair value
AI fair value
$34.82
as of Nov 10, 2026
Base case
$39.72
the single most likely path
Analyst consensus
$30.26
28 analysts · 12-month target
Price
$29.23
price 16% below the AI fair value

The price needs 4.0% growth a year for ten years. The AI thinks 8.0% is achievable, at a 22.0% margin.

At the 22% margin, the 4.0% required growth rate vs. 8.0% achievable creates a +4.0% positive gap, indicating Pfizer is undervalued with room for the company to exceed market expectations.

The business

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Last report Nov 3, 2026

Write why this business works, set your own fair value, and let the briefing speak only when a rule you wrote is crossed.

Start the thirty days · no card
General investment analysis · not personalized advice · the figures carry their dates